The Na(+)/H(+) exchanger: a target for cardiac therapeutic intervention.

M Karmazyn, M Sawyer, L Fliegel
{"title":"The Na(+)/H(+) exchanger: a target for cardiac therapeutic intervention.","authors":"M Karmazyn,&nbsp;M Sawyer,&nbsp;L Fliegel","doi":"10.2174/1568006054553417","DOIUrl":null,"url":null,"abstract":"<p><p>The Na(+)/H(+) exchanger (NHE) is a ubiquitous protein present in mammalian cells. In higher eukaryotes this integral membrane protein removes one intracellular H(+) for one extracellular Na(+) protecting cells from intracellular acidification. NHE is of essential importance in the myocardium. It prevents intracellular acidosis that inhibits contractility. NHE also plays a key role in damage to the mammalian myocardium that occurs during ischemia and reperfusion and is involved in hypertrophy of the myocardium. NHE is composed of a membrane bound domain of approximately 500 amino acids plus a hydrophilic regulatory cytoplasmic domain of approximately 315 amino acids. The NHE1 isoform is the only significant plasma membrane isoform present in the myocardium. The activity of NHE1 is elevated in animal models of myocardial infarcts and in left ventricular hypertrophy. During ischemia and reperfusion of the myocardium, NHE activity catalyzes increased uptake of intracellular sodium. This in turn is exchanged for extracellular calcium by the Na(+)/Ca(2+) exchanger resulting in calcium overload and damage to the myocardium. Numerous inhibitors of NHE have been developed to attempt to break this cycle of calcium overload. In animal models excellent success has been obtained in this regard. However in humans, clinical trials have resulted in only modest success and recently, significant detrimental side effects were note of one NHE inhibitor. The mechanisms by which these inhibitors affect NHE activity are presently being investigated and regions of the protein important in NHE activity and inhibitor efficacy are related but not identical. Future studies may develop superior inhibitors that may circumvent recently reported side effects. Recently, NHE inhibition has been shown to be remarkably effective in preventing hypertrophy in some animal models. Whether this proves to be a practical treatment for hypertrophy in humans has yet to be determined.</p>","PeriodicalId":84523,"journal":{"name":"Current drug targets. Cardiovascular & haematological disorders","volume":"5 4","pages":"323-35"},"PeriodicalIF":0.0000,"publicationDate":"2005-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568006054553417","citationCount":"104","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets. Cardiovascular & haematological disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1568006054553417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 104

Abstract

The Na(+)/H(+) exchanger (NHE) is a ubiquitous protein present in mammalian cells. In higher eukaryotes this integral membrane protein removes one intracellular H(+) for one extracellular Na(+) protecting cells from intracellular acidification. NHE is of essential importance in the myocardium. It prevents intracellular acidosis that inhibits contractility. NHE also plays a key role in damage to the mammalian myocardium that occurs during ischemia and reperfusion and is involved in hypertrophy of the myocardium. NHE is composed of a membrane bound domain of approximately 500 amino acids plus a hydrophilic regulatory cytoplasmic domain of approximately 315 amino acids. The NHE1 isoform is the only significant plasma membrane isoform present in the myocardium. The activity of NHE1 is elevated in animal models of myocardial infarcts and in left ventricular hypertrophy. During ischemia and reperfusion of the myocardium, NHE activity catalyzes increased uptake of intracellular sodium. This in turn is exchanged for extracellular calcium by the Na(+)/Ca(2+) exchanger resulting in calcium overload and damage to the myocardium. Numerous inhibitors of NHE have been developed to attempt to break this cycle of calcium overload. In animal models excellent success has been obtained in this regard. However in humans, clinical trials have resulted in only modest success and recently, significant detrimental side effects were note of one NHE inhibitor. The mechanisms by which these inhibitors affect NHE activity are presently being investigated and regions of the protein important in NHE activity and inhibitor efficacy are related but not identical. Future studies may develop superior inhibitors that may circumvent recently reported side effects. Recently, NHE inhibition has been shown to be remarkably effective in preventing hypertrophy in some animal models. Whether this proves to be a practical treatment for hypertrophy in humans has yet to be determined.

Na(+)/H(+)交换剂:心脏治疗干预的靶点。
Na(+)/H(+)交换器(NHE)是哺乳动物细胞中普遍存在的蛋白质。在高等真核生物中,这种完整的膜蛋白去除一个细胞内的H(+)和一个细胞外的Na(+),保护细胞免受细胞内酸化。NHE在心肌中具有至关重要的作用。它可以防止抑制收缩性的细胞内酸中毒。NHE在哺乳动物心肌缺血再灌注损伤中也起关键作用,并参与心肌肥厚。NHE由约500个氨基酸的膜结合结构域和约315个氨基酸的亲水性调节细胞质结构域组成。NHE1异构体是心肌中唯一重要的质膜异构体。心肌梗死和左心室肥厚动物模型中NHE1活性升高。在心肌缺血和再灌注期间,NHE活性催化细胞内钠的摄取增加。这反过来又通过Na(+)/Ca(2+)交换器交换为细胞外钙,导致钙过载和心肌损伤。许多NHE抑制剂已经被开发出来,试图打破这种钙超载的循环。在动物模型中,这方面已经取得了很好的成功。然而,在人类中,临床试验只取得了适度的成功,最近,一种NHE抑制剂的显著有害副作用被注意到。这些抑制剂影响NHE活性的机制目前正在研究中,对NHE活性和抑制剂功效重要的蛋白质区域相关但不相同。未来的研究可能会开发出更好的抑制剂,以避免最近报道的副作用。最近,在一些动物模型中,NHE抑制已被证明在预防肥大方面非常有效。这是否被证明是一种治疗人类肥厚的实用方法还有待确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书